We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05169515
Recruitment Status : Recruiting
First Posted : December 27, 2021
Last Update Posted : March 13, 2023
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and CC-99282) in participants with B-cell NHL.

Condition or disease Intervention/treatment Phase
Non-Hodgkin Lymphoma Drug: SC Mosunetuzumab Drug: IV Glofitamab Drug: CC-220 Drug: CC-99282 Drug: Obinutuzumab Drug: Tocilizumab Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
Actual Study Start Date : October 26, 2022
Estimated Primary Completion Date : April 15, 2025
Estimated Study Completion Date : April 15, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm 1
Participants will receive subcutaneous (SC) mosunetuzumab + CC-220 or SC mosunetuzumab + CC-99282.
 Drug: SC Mosunetuzumab
Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days for Cycle 1 and 28 days for Cycles 2-12)
Other Name: RO7030816

Drug: CC-220
Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-220 from Day 1-14 of Cycle 3-12 (cycle length = 21 days)

Drug: CC-99282
Arm 1: Participants will receive oral CC-99282 from Day 1-14 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-99282 from Day 1-10 of Cycle 3-12 (cycle length = 21 days)

Drug: Tocilizumab
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Other Name: RO4877533
Experimental: Arm 2
Participants will receive intravenous (IV) glofitamab + CC-220 or IV glofitamab + CC-99282.
 Drug: IV Glofitamab
Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
Other Name: RO7082859

Drug: CC-220
Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-220 from Day 1-14 of Cycle 3-12 (cycle length = 21 days)

Drug: CC-99282
Arm 1: Participants will receive oral CC-99282 from Day 1-14 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12) Arm 2: Participants will receive oral CC-99282 from Day 1-10 of Cycle 3-12 (cycle length = 21 days)

Drug: Obinutuzumab
Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
Other Name: RO5072759

Drug: Tocilizumab
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Other Name: RO4877533


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of participants with dose-limiting toxicities (DLTs) [dose escalation] [ Time Frame: Until 90 days after the final dose of study treatment ]
  2. Percentage of participants with adverse events [dose escalation] [ Time Frame: Until 90 days after the final dose of study treatment ]
  3. Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion] [ Time Frame: Up to 2 years after primary study treatment ]

Secondary Outcome Measures :
  1. Best CR rate, defined as the proportion of participants whose best overall response is a CR during the study, as determined by the investigator using Lugano 2014 criteria [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  2. Best ORR (CR or PR at any time) on study as determined by the investigator using Lugano 2014 criteria [dose escalation] [ Time Frame: Up to 2 years after primary study treatment ]
  3. Duration of response (DOR) as determined by the investigator using Lugano 2014 criteria [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  4. Progression-free survival (PFS) as determined by the investigator using Lugano 2014 criteria [dose expansion] [ Time Frame: Up to 2 years after primary study treatment ]
  5. Event-free survival (EFS) as determined by the investigator using Lugano 2014 criteria [dose expansion] [ Time Frame: Up to 2 years after primary study treatment ]
  6. Overall survival (OS) [dose expansion] [ Time Frame: Up to 2 years after primary study treatment ]
  7. Percentage of participants with adverse events [dose expansion] [ Time Frame: Until 90 days after the final dose of study treatment ]
  8. Maximum serum concentration (Cmax) of subcutaneous (SC) mosunetuzumab [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  9. Minimum serum concentration (Cmin) of mosunetuzumab SC [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  10. Total exposure (AUC) of mosunetuzumab SC [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  11. Apparent clearance (CL) of mosunetuzumab SC [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  12. Apparent volume of distribution of mosunetuzumab SC [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  13. Cmax of intravenous (IV) glofitamab [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  14. Cmin of glofitamab IV [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  15. AUC of glofitamab IV [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  16. CL of glofitamab IV [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  17. Volume of distribution of glofitamab IV [all cohorts] [ Time Frame: Up to 2 years after primary study treatment ]
  18. Cmax of CC-220 and CC-99282 (CELMoDs) [all cohorts] [ Time Frame: Up to 12 cycles of study treatment (cycle length = 21 or 28 days for Arm 1 and 21 days for Arm 2) ]
  19. Cmin of CELMoDs [all cohorts] [ Time Frame: Up to 12 cycles of study treatment (cycle length = 21 or 28 days for Arm 1 and 21 days for Arm 2) ]
  20. CL of CELMoDs [all cohorts] [ Time Frame: Up to 12 cycles of study treatment (cycle length = 21 or 28 days for Arm 1 and 21 days for Arm 2) ]
  21. Volume of distribution of CELMoDs [all cohorts] [ Time Frame: Up to 12 cycles of study treatment (cycle length = 21 or 28 days for Arm 1 and 21 days for Arm 2) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >/= 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
  • History of one of the following histologically documented hematologic malignancies that are expected to express the CD20 antigen: In the Dose Escalation phase, patients with R/R NHL who previously received at least two prior lines of systemic therapies can be enrolled. In the Dose Expansion phase, patients with FL (grade 1-3a), DLBCL/transformed FL who failed to respond to at least one prior line of systemic therapy can be potentially enrolled
  • Fluorodeoxyglucose-avid lymphoma (i.e. PET-positive lymphoma)
  • At least one bi-dimensionally measurable nodal lesion (> 1.5 cm in its largest dimension by PET/CT scan), or at least one bi-dimensionally measurable extranodal lesion (> 1.0 cm in its largest dimension by PET/CT scan)
  • Availability of a representative tumor specimen and the corresponding pathology report for confirmation of the diagnosis of NHL
  • A fresh pretreatment biopsy during screening period, excisional or incisional, is preferred
  • Adequate hematologic function without growth factors or blood product transfusion within 14 days of first dose of study drug administration
  • Normal laboratory values
  • All participants and health care providers will be trained and counseled on pregnancy prevention. For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for 3 months after the final dose of mosunetuzumab, at least 18 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, 28 days after the last dose of CC-220, 6 months and 2 weeks after the last dose of CC-99282, 3 months after the last dose of tocilizumab (if applicable), whichever is longer
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm during the treatment period and for at least 3 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, 90 days after the last dose of CC-220, 3 months and 2 weeks after the last dose of CC- 99282, 2 months after the final dose of tocilizumab (if applicable), whichever is longer

Exclusion Criteria:

  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study (female participants of childbearing potential must have a negative serum pregancy test result within 14 days prior to initiation of the study treatment)
  • Participant has received prior therapy with cereblon (CRBN)-modulating drug (e.g., lenalidomide, avadomide/CC-122, pomalidomide) </= 4 weeks prior to starting CC-220 and/or CC-99282
  • Inability to swallow pills, or persistent diarrhea or malabsorption >= Grade 2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), despite medical management
  • QTc interval of > 470 ms
  • The following treatments prior to study entry: mosunetuzumab, glofitamab, or other CD20/CD3-directed bispecific antibodies; allogenic stem cell therapy (SCT); solid organ transplantation
  • Treatments (investigation or approved) within the following time periods prior to initiation/first dose of study treatment: radiotherapy within 2 weeks; autologous SCT within 100 days; chimeric antigen receptor (CAR) T-cell therapy within 30 days; prior anti-lymphoma treatment with monoclonal antibodies or antibody-drug conjugates within 4 weeks; use of radioimmunoconjugates within 12 weeks; systemic immunosuppressive medications within 2 weeks; any other anti-cancer therapy, whether investigational or approved, including but not limited to chemotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter
  • Live, attenuated vaccine within 4 weeks before first dose of study treatment, or in whom it is anticipated that such a live attenuated vaccine will be required during the study period or within 5 months after the final dose of study treatment
  • Current or past history of central nervous system (CNS) lymphoma or leptomeningeal infiltration
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  • History of autoimmune disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
  • Major surgery or significant traumatic injury < 28 days prior to enrollment (excluding biopsies) or anticipation of the need for major surgery during study treatment
  • Clinically significant toxicities from prior treatment have not resolved to Grade </= 1 (per US national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5.0) prior to the first study drug administration with exceptions defined by the protocol
  • Evidence of any significant, concomitant disease (e.g. cardiovascular, pulmonary, liver, CVA or stroke, ILD, PML, infection, HLH etc) that could affect compliance with the protocol or interpretation of results
  • For participants enrolled into glofitamab cohort: documented refractoriness to an obinutuzumab monotherapy-containing regimen
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05169515


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: CO43805 https://forpatients.roche.com/ 888-662-6728 global-roche-genentech-trials@gene.com

Locations
Show Show 17 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT05169515    
Other Study ID Numbers: CO43805
First Posted: December 27, 2021    Key Record Dates
Last Update Posted: March 13, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
 Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Obinutuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents